Pharmacokinetics of vinorelbine in patients with liver metastases

Isabelle Robieux, Roberto Sorio, Eugenio Borsatti, Renato Cannizzaro, Vinicio Vitali, Paola Aita, Andrea Freschi, Enzo Galligioni, Silvio Monfardini

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Background: The main elimination pathway of vinorelbine is hepatic metabolism, and the clearance of vinorelbine could be reduced in patients with liver metastases. Objectives: To study the pharmacokinetics of vinorelbine in patients who have advanced breast cancer with or without liver metastases and to study the relationship between hepatic function and vinorelbine clearance. Patients and Methods: We studied 29 patients with advanced breast cancer: 19 with liver metastases and 10 control patients with extrahepatic metastases (mean age, 61 years; age range, 38 to 81 years). The vinorelbine dose was 30 mg/m2 as a short intravenous infusion; the dose was reduced by 50% in patients with bilirubin >2 mg/dl. Patients were classified by ultrasonographic estimation of the liver volume replaced by tumor (%LVRT), Standard liver function tests and a monoethylglycinexylidide test (a quantitative liver function test based on lidocaine metabolite formation) were performed, Vinorelbine was assayed in plasma by HPLC with fluorescence detection. Vinorelbine determination was impossible in two patients with more than 75% LVRT because of interferences. Pharmacokinetic parameters were calculated with a noncompartimental method and compared by means of the Kruskal-Wallis test. Results: A lower vinorelbine clearance rate was observed in the five patients with more than 75% LVRT (22.9 L/hr/m2) compared with the 10 patients with no liver metastases (48.0 L/hr/m2) and the 12 patients with 25% to 75% LVRT (45.3 L/hr/m2). Terminal elimination half-life and apparent volume of distribution were not significantly different among groups. The monoethylglycinexylidide test had a significant correlation with vinorelbine clearance, (r2 = 0.70; p = 10-4). Conclusions: These results support vinorelbine dose reduction in patients with severe liver failure but not in patients with moderate secondary liver involvement. The monoethylglycinexylidide test may prove to be useful for vinorelbine dose individualization.

Original languageEnglish
Pages (from-to)32-40
Number of pages9
JournalClinical Pharmacology and Therapeutics
Volume59
Issue number1
DOIs
Publication statusPublished - Jan 1996

Fingerprint

Pharmacokinetics
Neoplasm Metastasis
Liver
monoethylglycinexylidide
Liver Function Tests
vinorelbine
Breast Neoplasms
Liver Failure
Lidocaine
Tumor Burden
Bilirubin
Intravenous Infusions
Half-Life
Fluorescence
High Pressure Liquid Chromatography

ASJC Scopus subject areas

  • Pharmacology

Cite this

Pharmacokinetics of vinorelbine in patients with liver metastases. / Robieux, Isabelle; Sorio, Roberto; Borsatti, Eugenio; Cannizzaro, Renato; Vitali, Vinicio; Aita, Paola; Freschi, Andrea; Galligioni, Enzo; Monfardini, Silvio.

In: Clinical Pharmacology and Therapeutics, Vol. 59, No. 1, 01.1996, p. 32-40.

Research output: Contribution to journalArticle

Robieux, Isabelle ; Sorio, Roberto ; Borsatti, Eugenio ; Cannizzaro, Renato ; Vitali, Vinicio ; Aita, Paola ; Freschi, Andrea ; Galligioni, Enzo ; Monfardini, Silvio. / Pharmacokinetics of vinorelbine in patients with liver metastases. In: Clinical Pharmacology and Therapeutics. 1996 ; Vol. 59, No. 1. pp. 32-40.
@article{22a7bc91a84c4e8cadfed10bfe611add,
title = "Pharmacokinetics of vinorelbine in patients with liver metastases",
abstract = "Background: The main elimination pathway of vinorelbine is hepatic metabolism, and the clearance of vinorelbine could be reduced in patients with liver metastases. Objectives: To study the pharmacokinetics of vinorelbine in patients who have advanced breast cancer with or without liver metastases and to study the relationship between hepatic function and vinorelbine clearance. Patients and Methods: We studied 29 patients with advanced breast cancer: 19 with liver metastases and 10 control patients with extrahepatic metastases (mean age, 61 years; age range, 38 to 81 years). The vinorelbine dose was 30 mg/m2 as a short intravenous infusion; the dose was reduced by 50{\%} in patients with bilirubin >2 mg/dl. Patients were classified by ultrasonographic estimation of the liver volume replaced by tumor ({\%}LVRT), Standard liver function tests and a monoethylglycinexylidide test (a quantitative liver function test based on lidocaine metabolite formation) were performed, Vinorelbine was assayed in plasma by HPLC with fluorescence detection. Vinorelbine determination was impossible in two patients with more than 75{\%} LVRT because of interferences. Pharmacokinetic parameters were calculated with a noncompartimental method and compared by means of the Kruskal-Wallis test. Results: A lower vinorelbine clearance rate was observed in the five patients with more than 75{\%} LVRT (22.9 L/hr/m2) compared with the 10 patients with no liver metastases (48.0 L/hr/m2) and the 12 patients with 25{\%} to 75{\%} LVRT (45.3 L/hr/m2). Terminal elimination half-life and apparent volume of distribution were not significantly different among groups. The monoethylglycinexylidide test had a significant correlation with vinorelbine clearance, (r2 = 0.70; p = 10-4). Conclusions: These results support vinorelbine dose reduction in patients with severe liver failure but not in patients with moderate secondary liver involvement. The monoethylglycinexylidide test may prove to be useful for vinorelbine dose individualization.",
author = "Isabelle Robieux and Roberto Sorio and Eugenio Borsatti and Renato Cannizzaro and Vinicio Vitali and Paola Aita and Andrea Freschi and Enzo Galligioni and Silvio Monfardini",
year = "1996",
month = "1",
doi = "10.1016/S0009-9236(96)90021-1",
language = "English",
volume = "59",
pages = "32--40",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Pharmacokinetics of vinorelbine in patients with liver metastases

AU - Robieux, Isabelle

AU - Sorio, Roberto

AU - Borsatti, Eugenio

AU - Cannizzaro, Renato

AU - Vitali, Vinicio

AU - Aita, Paola

AU - Freschi, Andrea

AU - Galligioni, Enzo

AU - Monfardini, Silvio

PY - 1996/1

Y1 - 1996/1

N2 - Background: The main elimination pathway of vinorelbine is hepatic metabolism, and the clearance of vinorelbine could be reduced in patients with liver metastases. Objectives: To study the pharmacokinetics of vinorelbine in patients who have advanced breast cancer with or without liver metastases and to study the relationship between hepatic function and vinorelbine clearance. Patients and Methods: We studied 29 patients with advanced breast cancer: 19 with liver metastases and 10 control patients with extrahepatic metastases (mean age, 61 years; age range, 38 to 81 years). The vinorelbine dose was 30 mg/m2 as a short intravenous infusion; the dose was reduced by 50% in patients with bilirubin >2 mg/dl. Patients were classified by ultrasonographic estimation of the liver volume replaced by tumor (%LVRT), Standard liver function tests and a monoethylglycinexylidide test (a quantitative liver function test based on lidocaine metabolite formation) were performed, Vinorelbine was assayed in plasma by HPLC with fluorescence detection. Vinorelbine determination was impossible in two patients with more than 75% LVRT because of interferences. Pharmacokinetic parameters were calculated with a noncompartimental method and compared by means of the Kruskal-Wallis test. Results: A lower vinorelbine clearance rate was observed in the five patients with more than 75% LVRT (22.9 L/hr/m2) compared with the 10 patients with no liver metastases (48.0 L/hr/m2) and the 12 patients with 25% to 75% LVRT (45.3 L/hr/m2). Terminal elimination half-life and apparent volume of distribution were not significantly different among groups. The monoethylglycinexylidide test had a significant correlation with vinorelbine clearance, (r2 = 0.70; p = 10-4). Conclusions: These results support vinorelbine dose reduction in patients with severe liver failure but not in patients with moderate secondary liver involvement. The monoethylglycinexylidide test may prove to be useful for vinorelbine dose individualization.

AB - Background: The main elimination pathway of vinorelbine is hepatic metabolism, and the clearance of vinorelbine could be reduced in patients with liver metastases. Objectives: To study the pharmacokinetics of vinorelbine in patients who have advanced breast cancer with or without liver metastases and to study the relationship between hepatic function and vinorelbine clearance. Patients and Methods: We studied 29 patients with advanced breast cancer: 19 with liver metastases and 10 control patients with extrahepatic metastases (mean age, 61 years; age range, 38 to 81 years). The vinorelbine dose was 30 mg/m2 as a short intravenous infusion; the dose was reduced by 50% in patients with bilirubin >2 mg/dl. Patients were classified by ultrasonographic estimation of the liver volume replaced by tumor (%LVRT), Standard liver function tests and a monoethylglycinexylidide test (a quantitative liver function test based on lidocaine metabolite formation) were performed, Vinorelbine was assayed in plasma by HPLC with fluorescence detection. Vinorelbine determination was impossible in two patients with more than 75% LVRT because of interferences. Pharmacokinetic parameters were calculated with a noncompartimental method and compared by means of the Kruskal-Wallis test. Results: A lower vinorelbine clearance rate was observed in the five patients with more than 75% LVRT (22.9 L/hr/m2) compared with the 10 patients with no liver metastases (48.0 L/hr/m2) and the 12 patients with 25% to 75% LVRT (45.3 L/hr/m2). Terminal elimination half-life and apparent volume of distribution were not significantly different among groups. The monoethylglycinexylidide test had a significant correlation with vinorelbine clearance, (r2 = 0.70; p = 10-4). Conclusions: These results support vinorelbine dose reduction in patients with severe liver failure but not in patients with moderate secondary liver involvement. The monoethylglycinexylidide test may prove to be useful for vinorelbine dose individualization.

UR - http://www.scopus.com/inward/record.url?scp=0030042231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030042231&partnerID=8YFLogxK

U2 - 10.1016/S0009-9236(96)90021-1

DO - 10.1016/S0009-9236(96)90021-1

M3 - Article

C2 - 8549031

AN - SCOPUS:0030042231

VL - 59

SP - 32

EP - 40

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 1

ER -